本报道最初发表于Endpoints News。请点击这里查看原文
MoonLake Immunotherapeutics’ only investigational drug showed a clinically meaningful benefit in patients with an aggressive form of inflammatory arthritis, according to Phase 2 data the company shared with Endpoints News on Sunday.
据MoonLake Immunotherapeutics周日向Endpoints News分享的二期临床试验数据，其唯一investigational drug在患有侵袭性炎性关节炎的患者中显示出具有临床意义的获益。
您已阅读7%（372字），剩余93%（5087字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。